Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia

Ligia Mendes Soares; Jos Prickaerts; Humberto Milani; Elaine Del Bel; Harry Wilhelm Maria Steinbusch; Rubia Maria Weffort de Oliveira

doi:10.2174/1871527314666150909114249

Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia

Ligia Mendes Soares, Jos Prickaerts, Humberto Milani, Elaine Del Bel, Harry Wilhelm Maria Steinbusch, Rubia Maria Weffort de Oliveira^*

^*Corresponding author for this work

MHeNs - Neuroscience

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Preclinical studies have shown that phosphodiesterase inhibitors (PDE-Is) represent a potential pharmacological strategy for the treatment of brain ischemia sequelea. PDE-Is 3, 4 and 5 have been tested in several brain ischemia models. All the three PDE-Is after acute or chronic treatment decreased the degree of neurodegeneration and most of them improved functional recovery after brain injury by specific cellular and molecular mechanisms mainly involving an anti-inflammatory and/or neuroprotection action. In contrast to the large number of investigations using PDE-Is in experimental brain ischemia research, the number of clinical studies is still limited. The purpose of this review is to summarize the data currently available on the effects of PDE-Is in experimental models of cerebral ischemia.

Original language	English
Pages (from-to)	1012-1023
Journal	Cns & Neurological Disorders-Drug Targets
Volume	14
Issue number	8
DOIs	https://doi.org/10.2174/1871527314666150909114249
Publication status	Published - 2015

Keywords

Animal models
brain ischemia
stroke
phosphodiesterase inhibitors

Access to Document

10.2174/1871527314666150909114249

Cite this

@article{6bd26890e0e14257862731e770d92223,

title = "Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia",

abstract = "Preclinical studies have shown that phosphodiesterase inhibitors (PDE-Is) represent a potential pharmacological strategy for the treatment of brain ischemia sequelea. PDE-Is 3, 4 and 5 have been tested in several brain ischemia models. All the three PDE-Is after acute or chronic treatment decreased the degree of neurodegeneration and most of them improved functional recovery after brain injury by specific cellular and molecular mechanisms mainly involving an anti-inflammatory and/or neuroprotection action. In contrast to the large number of investigations using PDE-Is in experimental brain ischemia research, the number of clinical studies is still limited. The purpose of this review is to summarize the data currently available on the effects of PDE-Is in experimental models of cerebral ischemia.",

keywords = "Animal models, brain ischemia, stroke, phosphodiesterase inhibitors",

author = "Soares, {Ligia Mendes} and Jos Prickaerts and Humberto Milani and {Del Bel}, Elaine and Steinbusch, {Harry Wilhelm Maria} and {Weffort de Oliveira}, {Rubia Maria}",

year = "2015",

doi = "10.2174/1871527314666150909114249",

language = "English",

volume = "14",

pages = "1012--1023",

journal = "Cns & Neurological Disorders-Drug Targets",

issn = "1871-5273",

publisher = "Bentham Science Publishers",

number = "8",

}

TY - JOUR

T1 - Phosphodiesterase Inhibition as a Therapeutic Target for Brain Ischemia

AU - Soares, Ligia Mendes

AU - Prickaerts, Jos

AU - Milani, Humberto

AU - Del Bel, Elaine

AU - Steinbusch, Harry Wilhelm Maria

AU - Weffort de Oliveira, Rubia Maria

PY - 2015

Y1 - 2015

N2 - Preclinical studies have shown that phosphodiesterase inhibitors (PDE-Is) represent a potential pharmacological strategy for the treatment of brain ischemia sequelea. PDE-Is 3, 4 and 5 have been tested in several brain ischemia models. All the three PDE-Is after acute or chronic treatment decreased the degree of neurodegeneration and most of them improved functional recovery after brain injury by specific cellular and molecular mechanisms mainly involving an anti-inflammatory and/or neuroprotection action. In contrast to the large number of investigations using PDE-Is in experimental brain ischemia research, the number of clinical studies is still limited. The purpose of this review is to summarize the data currently available on the effects of PDE-Is in experimental models of cerebral ischemia.

AB - Preclinical studies have shown that phosphodiesterase inhibitors (PDE-Is) represent a potential pharmacological strategy for the treatment of brain ischemia sequelea. PDE-Is 3, 4 and 5 have been tested in several brain ischemia models. All the three PDE-Is after acute or chronic treatment decreased the degree of neurodegeneration and most of them improved functional recovery after brain injury by specific cellular and molecular mechanisms mainly involving an anti-inflammatory and/or neuroprotection action. In contrast to the large number of investigations using PDE-Is in experimental brain ischemia research, the number of clinical studies is still limited. The purpose of this review is to summarize the data currently available on the effects of PDE-Is in experimental models of cerebral ischemia.

KW - Animal models

KW - brain ischemia

KW - stroke

KW - phosphodiesterase inhibitors

U2 - 10.2174/1871527314666150909114249

DO - 10.2174/1871527314666150909114249

M3 - Article

C2 - 26350339

SN - 1871-5273

VL - 14

SP - 1012

EP - 1023

JO - Cns & Neurological Disorders-Drug Targets

JF - Cns & Neurological Disorders-Drug Targets

IS - 8

ER -